Rational design of isonicotinic acid hydrazide derivatives with antitubercular activity: Machine learning, molecular docking, synthesis and biological testing. 2018

Vasyl Kovalishyn, and Julie Grouleff, and Ivan Semenyuta, and Vitaliy O Sinenko, and Sergiy R Slivchuk, and Diana Hodyna, and Volodymyr Brovarets, and Volodymyr Blagodatny, and Gennady Poda, and Igor V Tetko, and Larysa Metelytsia
Institute of Bioorganic Chemistry and Petrochemistry, National Academy of Science of Ukraine, Kyiv, Ukraine.

The problem of designing new antitubercular drugs against multiple drug-resistant tuberculosis (MDR-TB) was addressed using advanced machine learning methods. As there are only few published measurements against MDR-TB, we collected a large literature data set and developed models against the non-resistant H37Rv strain. The predictive accuracy of these models had a coefficient of determination q2  = .7-.8 (regression models) and balanced accuracies of about 80% (classification models) with cross-validation and independent test sets. The models were applied to screen a virtual chemical library, which was designed to have MDR-TB activity. The seven most promising compounds were identified, synthesized and tested. All of them showed activity against the H37Rv strain, and three molecules demonstrated activity against the MDR-TB strain. The docking analysis indicated that the discovered molecules could bind enoyl reductase, InhA, which is required in mycobacterial cell wall development. The models are freely available online (http://ochem.eu/article/103868) and can be used to predict potential anti-TB activity of new chemicals.

UI MeSH Term Description Entries
D007538 Isoniazid Antibacterial agent used primarily as a tuberculostatic. It remains the treatment of choice for tuberculosis. Isonicotinic Acid Hydrazide,Ftivazide,Isonex,Isonicotinic Acid Vanillylidenehydrazide,Phthivazid,Phthivazide,Tubazide,Acid Vanillylidenehydrazide, Isonicotinic,Hydrazide, Isonicotinic Acid,Vanillylidenehydrazide, Isonicotinic Acid
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D009169 Mycobacterium tuberculosis A species of gram-positive, aerobic bacteria that produces TUBERCULOSIS in humans, other primates, CATTLE; DOGS; and some other animals which have contact with humans. Growth tends to be in serpentine, cordlike masses in which the bacilli show a parallel orientation. Mycobacterium tuberculosis H37Rv
D010088 Oxidoreductases The class of all enzymes catalyzing oxidoreduction reactions. The substrate that is oxidized is regarded as a hydrogen donor. The systematic name is based on donor:acceptor oxidoreductase. The recommended name will be dehydrogenase, wherever this is possible; as an alternative, reductase can be used. Oxidase is only used in cases where O2 is the acceptor. (Enzyme Nomenclature, 1992, p9) Dehydrogenases,Oxidases,Oxidoreductase,Reductases,Dehydrogenase,Oxidase,Reductase
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000069550 Machine Learning A type of ARTIFICIAL INTELLIGENCE that enable COMPUTERS to independently initiate and execute LEARNING when exposed to new data. Transfer Learning,Learning, Machine,Learning, Transfer
D000995 Antitubercular Agents Drugs used in the treatment of tuberculosis. They are divided into two main classes: "first-line" agents, those with the greatest efficacy and acceptable degrees of toxicity used successfully in the great majority of cases; and "second-line" drugs used in drug-resistant cases or those in which some other patient-related condition has compromised the effectiveness of primary therapy. Anti-Tuberculosis Agent,Anti-Tuberculosis Agents,Anti-Tuberculosis Drug,Anti-Tuberculosis Drugs,Antitubercular Agent,Antitubercular Drug,Tuberculostatic Agent,Tuberculostatic Agents,Antitubercular Drugs,Agent, Anti-Tuberculosis,Agent, Antitubercular,Agent, Tuberculostatic,Anti Tuberculosis Agent,Anti Tuberculosis Agents,Anti Tuberculosis Drug,Anti Tuberculosis Drugs,Drug, Anti-Tuberculosis,Drug, Antitubercular
D001426 Bacterial Proteins Proteins found in any species of bacterium. Bacterial Gene Products,Bacterial Gene Proteins,Gene Products, Bacterial,Bacterial Gene Product,Bacterial Gene Protein,Bacterial Protein,Gene Product, Bacterial,Gene Protein, Bacterial,Gene Proteins, Bacterial,Protein, Bacterial,Proteins, Bacterial
D001665 Binding Sites The parts of a macromolecule that directly participate in its specific combination with another molecule. Combining Site,Binding Site,Combining Sites,Site, Binding,Site, Combining,Sites, Binding,Sites, Combining
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs

Related Publications

Vasyl Kovalishyn, and Julie Grouleff, and Ivan Semenyuta, and Vitaliy O Sinenko, and Sergiy R Slivchuk, and Diana Hodyna, and Volodymyr Brovarets, and Volodymyr Blagodatny, and Gennady Poda, and Igor V Tetko, and Larysa Metelytsia
January 2020, Current drug discovery technologies,
Vasyl Kovalishyn, and Julie Grouleff, and Ivan Semenyuta, and Vitaliy O Sinenko, and Sergiy R Slivchuk, and Diana Hodyna, and Volodymyr Brovarets, and Volodymyr Blagodatny, and Gennady Poda, and Igor V Tetko, and Larysa Metelytsia
January 1978, TSitologiia i genetika,
Vasyl Kovalishyn, and Julie Grouleff, and Ivan Semenyuta, and Vitaliy O Sinenko, and Sergiy R Slivchuk, and Diana Hodyna, and Volodymyr Brovarets, and Volodymyr Blagodatny, and Gennady Poda, and Igor V Tetko, and Larysa Metelytsia
April 1952, Comptes rendus des seances de la Societe de biologie et de ses filiales,
Vasyl Kovalishyn, and Julie Grouleff, and Ivan Semenyuta, and Vitaliy O Sinenko, and Sergiy R Slivchuk, and Diana Hodyna, and Volodymyr Brovarets, and Volodymyr Blagodatny, and Gennady Poda, and Igor V Tetko, and Larysa Metelytsia
May 1952, Minerva medica,
Vasyl Kovalishyn, and Julie Grouleff, and Ivan Semenyuta, and Vitaliy O Sinenko, and Sergiy R Slivchuk, and Diana Hodyna, and Volodymyr Brovarets, and Volodymyr Blagodatny, and Gennady Poda, and Igor V Tetko, and Larysa Metelytsia
June 1963, El Dia medico,
Vasyl Kovalishyn, and Julie Grouleff, and Ivan Semenyuta, and Vitaliy O Sinenko, and Sergiy R Slivchuk, and Diana Hodyna, and Volodymyr Brovarets, and Volodymyr Blagodatny, and Gennady Poda, and Igor V Tetko, and Larysa Metelytsia
October 2023, Physical chemistry chemical physics : PCCP,
Vasyl Kovalishyn, and Julie Grouleff, and Ivan Semenyuta, and Vitaliy O Sinenko, and Sergiy R Slivchuk, and Diana Hodyna, and Volodymyr Brovarets, and Volodymyr Blagodatny, and Gennady Poda, and Igor V Tetko, and Larysa Metelytsia
May 1952, Minerva medica,
Vasyl Kovalishyn, and Julie Grouleff, and Ivan Semenyuta, and Vitaliy O Sinenko, and Sergiy R Slivchuk, and Diana Hodyna, and Volodymyr Brovarets, and Volodymyr Blagodatny, and Gennady Poda, and Igor V Tetko, and Larysa Metelytsia
March 2022, International journal of molecular sciences,
Vasyl Kovalishyn, and Julie Grouleff, and Ivan Semenyuta, and Vitaliy O Sinenko, and Sergiy R Slivchuk, and Diana Hodyna, and Volodymyr Brovarets, and Volodymyr Blagodatny, and Gennady Poda, and Igor V Tetko, and Larysa Metelytsia
June 2022, Chemistry & biodiversity,
Vasyl Kovalishyn, and Julie Grouleff, and Ivan Semenyuta, and Vitaliy O Sinenko, and Sergiy R Slivchuk, and Diana Hodyna, and Volodymyr Brovarets, and Volodymyr Blagodatny, and Gennady Poda, and Igor V Tetko, and Larysa Metelytsia
October 2018, Bioorganic chemistry,
Copied contents to your clipboard!